<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-7920 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-7920</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-7920</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-147.html">extraction-schema-147</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causal mechanisms for Alzheimer's disease, associated risk factors, supporting and contradictory evidence, and methods for detecting the disease, including biomarkers, imaging techniques, cognitive and digital assessments, together with reported diagnostic performance and study details.</div>
                <p><strong>Paper ID:</strong> paper-278198018</p>
                <p><strong>Paper Title:</strong> Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease</p>
                <p><strong>Paper Abstract:</strong> Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by impairments in memory and cognitive abilities. The development of new immunotherapies targeting beta-amyloid (Aβ) and tau protein deposition in the brain is ushering in great advances in clinical management. Advances in molecular imaging techniques, particularly positron emission tomography (PET) with amyloid and tau tracers, have facilitated the early detection of Alzheimer's pathology. We report a case of a 67-year-old patient presenting with mild cognitive impairment (MCI) who was confirmed to have AD on newer PET imaging. This report highlights the important role of molecular imaging in the early diagnosis of AD before significant clinical and functional decline sets in, thereby emphasizing its role in clinical practice.</p>
                <p><strong>Cost:</strong> 0.012</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e7920.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e7920.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causal mechanisms for Alzheimer's disease, associated risk factors, supporting and contradictory evidence, and methods for detecting the disease, including biomarkers, imaging techniques, cognitive and digital assessments, together with reported diagnostic performance and study details.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amyloid cascade</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid cascade hypothesis (Aβ plaque deposition)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Proposed causal mechanism in which extracellular beta-amyloid (Aβ) plaque deposition initiates a cascade leading to synaptic dysfunction and neuronal death, driving Alzheimer's disease pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_name</strong></td>
                            <td>amyloid cascade</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_description</strong></td>
                            <td>Extracellular aggregation and deposition of beta-amyloid (Aβ) in brain grey matter triggers downstream neurodegenerative processes (synaptic dysfunction, tau pathology, neuronal death) that produce cognitive decline in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>The paper cites in vivo amyloid PET imaging (F-18 Florbetapir) that visualizes Aβ deposition and reports a clinical case with positive amyloid PET; literature cited indicates amyloid PET can detect Aβ deposition early and is used to select patients for anti-Aβ therapies (e.g., aducanumab, lecanemab). Reported literature diagnostic performance for best PET measures: sensitivity 88-91% and specificity 80-84% for presence of beta-amyloid deposition.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>Authors note limited specificity of clinical diagnosis: neuropathological studies find amyloid plaques and neurofibrillary tangles in only ~85% of clinically diagnosed AD dementia, indicating mismatch between clinical diagnosis and underlying Aβ pathology; the paper also references that CSF and PET modalities have differences in timing (amyloid PET may detect deposition earlier than CSF), implying complexities in relying solely on Aβ measures.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor</strong></td>
                            <td>APOE gene / family history of early-onset AD (as discussed in the paper's case and text)</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor_category</strong></td>
                            <td>genetic</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Amyloid PET (F-18 Florbetapir)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>imaging</td>
                        </tr>
                        <tr>
                            <td><strong>diagnostic_performance</strong></td>
                            <td>For best PET measures detecting beta-amyloid deposition reported in the literature: sensitivity 88-91%, specificity 80-84% (no confidence intervals provided in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Reported from literature summaries referenced in the paper (design details not specified in this article).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>population_characteristics</strong></td>
                            <td>Described generally as patients with suspected AD or MCI; exact cohorts for the quoted performance metrics are not specified in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease', 'publication_date_yy_mm': '2025-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e7920.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e7920.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causal mechanisms for Alzheimer's disease, associated risk factors, supporting and contradictory evidence, and methods for detecting the disease, including biomarkers, imaging techniques, cognitive and digital assessments, together with reported diagnostic performance and study details.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tau propagation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tau propagation / intracellular neurofibrillary tangles hypothesis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Hypothesis that intracellular aggregation of hyperphosphorylated tau into neurofibrillary tangles impairs neuronal function and spreads in a stereotyped manner, driving disease progression and cognitive decline in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_name</strong></td>
                            <td>tau propagation</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_description</strong></td>
                            <td>Intracellular accumulation of hyperphosphorylated tau forms tangles that disrupt neuronal cytoskeleton and synaptic function, contributing to neuronal death and correlating with clinical stage and progression of AD.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>The paper reports direct visualization of tau pathology by tau PET (F-18 GTP1) in the presented case (temporoparietal tau accumulation), and notes that tau PET is critical for staging disease progression; the clinical trial enrollment of the patient into a tau-targeting monoclonal antibody (semorinemab) is cited as clinical translation of tau-targeted therapies.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>Paper does not present direct contradictory molecular evidence to tau hypothesis; it does note limitations in clinical-pathological concordance (amyloid/tau pathology present in ~85% of clinical AD), implying that tau pathology is not universally present in all clinically diagnosed cases.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor</strong></td>
                            <td>Family history of early-onset Alzheimer's disease (patient's father)</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor_category</strong></td>
                            <td>genetic</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Tau PET (F-18 GTP1)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>imaging</td>
                        </tr>
                        <tr>
                            <td><strong>diagnostic_performance</strong></td>
                            <td>No numeric sensitivity/specificity provided for tau PET performance in this paper; its utility is described qualitatively (detects tau tangles, useful for staging).</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Case report (this paper reports use of tau PET in a single patient) and literature discussion; broader performance metrics are not specified.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>1</td>
                        </tr>
                        <tr>
                            <td><strong>population_characteristics</strong></td>
                            <td>62-year-old right-handed female with progressive short-term memory loss, MMSE 26/30, family history of early-onset AD; enrolled in a tau-targeting clinical trial.</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease', 'publication_date_yy_mm': '2025-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e7920.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e7920.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causal mechanisms for Alzheimer's disease, associated risk factors, supporting and contradictory evidence, and methods for detecting the disease, including biomarkers, imaging techniques, cognitive and digital assessments, together with reported diagnostic performance and study details.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neurodegeneration (A/T/N 'N')</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neurodegeneration / neuronal injury biomarker (N in A/T/N)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Neurodegeneration reflected by structural loss or hypometabolism (MRI atrophy, FDG-PET hypometabolism, CSF t-tau) used as a marker of neuronal injury and disease stage.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_name</strong></td>
                            <td>neurodegeneration (metabolic dysfunction / neuronal injury)</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_description</strong></td>
                            <td>Neuronal injury and metabolic dysfunction (reflected as cortical atrophy on MRI and regional hypometabolism on FDG-PET) are downstream manifestations of AD pathology and correlate with cognitive impairment and disease stage.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>In the case, MRI showed cortical atrophy (temporal/parietal) and F-18 FDG PET showed hypometabolism in bilateral temporal and parietal lobes—findings consistent with AD pattern; the paper references FDG-PET aiding differentiation of AD from other dementias and lists structural MRI and diffusion tensor imaging as methods to reveal atrophy and white matter changes.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>No direct contradictory evidence presented in this article; authors note that structural changes often appear later in disease progression, limiting early-detection utility.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor</strong></td>
                            <td>Age (AD primarily affects individuals aged 65 and older as noted in the paper)</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor_category</strong></td>
                            <td>demographic/age</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>FDG-PET (regional hypometabolism); MRI (cortical/hippocampal atrophy); diffusion tensor imaging (white matter microstructural changes)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>imaging</td>
                        </tr>
                        <tr>
                            <td><strong>diagnostic_performance</strong></td>
                            <td>Paper does not provide numeric diagnostic metrics for FDG-PET or MRI in this article beyond qualitative descriptions; FDG-PET pattern described qualitatively as 'suggestive of Alzheimer's disease pattern.'</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Use in single-case clinical evaluation reported in this paper; referenced literature for general utility (designs not specified here).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>1</td>
                        </tr>
                        <tr>
                            <td><strong>population_characteristics</strong></td>
                            <td>Single 62-year-old female with MCI symptoms, MMSE 26/30; MRI and FDG-PET abnormalities consistent with AD pattern.</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease', 'publication_date_yy_mm': '2025-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e7920.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e7920.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causal mechanisms for Alzheimer's disease, associated risk factors, supporting and contradictory evidence, and methods for detecting the disease, including biomarkers, imaging techniques, cognitive and digital assessments, together with reported diagnostic performance and study details.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF biomarker ratios</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CSF Aβ42 / t-tau and Aβ42 / p-tau ratios</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Cerebrospinal fluid biomarker ratios combining Aβ42 with total tau or phosphorylated tau used to identify AD pathology and predict conversion in MCI patients.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_name</strong></td>
                            <td>fluid-biomarker indication of Aβ/tau pathology</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_description</strong></td>
                            <td>Altered CSF concentrations (reduced Aβ42 and increased t-tau/p-tau) and their ratios reflect underlying amyloid and tau pathologies and can identify patients with MCI likely due to AD.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>The paper cites literature reporting high diagnostic performance for CSF Aβ42/t-tau and Aβ42/p-tau ratios in identifying MCI-AD: sensitivity 94-97% and specificity 83-85%; CSF biomarkers are described as well-validated for in vivo detection of AD pathology and used in research and clinical contexts.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>In the presented case, routine CSF analysis (cell count, glucose, protein) was unremarkable, illustrating that standard CSF testing (not specialized Aβ/tau assays) may be normal; the paper also references differences in timing between PET and CSF (amyloid PET may detect deposition earlier than CSF), indicating discordance in some situations.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor</strong></td>
                            <td>Mild cognitive impairment (MCI) stage as the clinical context for CSF biomarker use</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor_category</strong></td>
                            <td>clinical stage</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>CSF measurement of Aβ42, total tau (t-tau), and hyperphosphorylated tau (p-tau); use of Aβ42/t-tau and Aβ42/p-tau ratios</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>fluid biomarker</td>
                        </tr>
                        <tr>
                            <td><strong>diagnostic_performance</strong></td>
                            <td>Reported in the paper from cited literature: sensitivity 94-97% and specificity 83-85% for identifying MCI patients with suspected AD (no further metrics or study-level detail provided here).</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Reported from multi-cohort / literature studies cited in the article (exact designs not specified in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>population_characteristics</strong></td>
                            <td>Described for MCI patients suspected of AD (MCI-AD) in cited literature; this paper's case had routine CSF testing but not reported specialized Aβ/tau CSF results.</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease', 'publication_date_yy_mm': '2025-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e7920.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e7920.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causal mechanisms for Alzheimer's disease, associated risk factors, supporting and contradictory evidence, and methods for detecting the disease, including biomarkers, imaging techniques, cognitive and digital assessments, together with reported diagnostic performance and study details.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Clinical cognitive assessment (MMSE)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mini-Mental State Examination (MMSE)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Brief clinician-administered cognitive screening tool used to quantify cognitive impairment; used here in initial neuropsychological assessment.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_name</strong></td>
                            <td>clinical cognitive dysfunction measurement</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_description</strong></td>
                            <td>Cognitive screening tests detect clinical impairment that may prompt further biomarker-based evaluation; while useful, clinical tests alone often identify AD at later stages compared with biomarker approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>In the case, MMSE score was 26/30, demonstrating mild cognitive impairment; the paper emphasizes that traditional clinical/neuropsychological testing often identifies AD at a relatively late stage and supports the need for biomarker-based early detection.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_evidence</strong></td>
                            <td>Authors state that clinical criteria have limited specificity for underlying AD neuropathology (only ~85% concordance), indicating MMSE and clinical assessment alone can be insufficient to reliably identify AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor</strong></td>
                            <td>Mild cognitive impairment (as indicated by lower MMSE scores)</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factor_category</strong></td>
                            <td>clinical</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Mini-Mental State Examination (MMSE)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>cognitive test</td>
                        </tr>
                        <tr>
                            <td><strong>diagnostic_performance</strong></td>
                            <td>No numeric sensitivity/specificity provided in this paper for MMSE performance; MMSE score reported for single case (26/30).</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Use in single-case clinical evaluation in this paper (case report).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>1</td>
                        </tr>
                        <tr>
                            <td><strong>population_characteristics</strong></td>
                            <td>Single 62-year-old female with progressive short-term memory loss and MMSE 26/30 (interpreted as mild cognitive impairment).</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease', 'publication_date_yy_mm': '2025-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>NIA-AA Research Framework: toward a biological definition of Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions <em>(Rating: 2)</em></li>
                <li>Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study <em>(Rating: 2)</em></li>
                <li>Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Lecanemab in early Alzheimer's disease <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-7920",
    "paper_id": "paper-278198018",
    "extraction_schema_id": "extraction-schema-147",
    "extracted_data": [
        {
            "name_short": "Amyloid cascade",
            "name_full": "Amyloid cascade hypothesis (Aβ plaque deposition)",
            "brief_description": "Proposed causal mechanism in which extracellular beta-amyloid (Aβ) plaque deposition initiates a cascade leading to synaptic dysfunction and neuronal death, driving Alzheimer's disease pathology.",
            "citation_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease",
            "mention_or_use": "mention",
            "hypothesis_name": "amyloid cascade",
            "hypothesis_description": "Extracellular aggregation and deposition of beta-amyloid (Aβ) in brain grey matter triggers downstream neurodegenerative processes (synaptic dysfunction, tau pathology, neuronal death) that produce cognitive decline in AD.",
            "supporting_evidence": "The paper cites in vivo amyloid PET imaging (F-18 Florbetapir) that visualizes Aβ deposition and reports a clinical case with positive amyloid PET; literature cited indicates amyloid PET can detect Aβ deposition early and is used to select patients for anti-Aβ therapies (e.g., aducanumab, lecanemab). Reported literature diagnostic performance for best PET measures: sensitivity 88-91% and specificity 80-84% for presence of beta-amyloid deposition.",
            "contradictory_evidence": "Authors note limited specificity of clinical diagnosis: neuropathological studies find amyloid plaques and neurofibrillary tangles in only ~85% of clinically diagnosed AD dementia, indicating mismatch between clinical diagnosis and underlying Aβ pathology; the paper also references that CSF and PET modalities have differences in timing (amyloid PET may detect deposition earlier than CSF), implying complexities in relying solely on Aβ measures.",
            "risk_factor": "APOE gene / family history of early-onset AD (as discussed in the paper's case and text)",
            "risk_factor_category": "genetic",
            "detection_method": "Amyloid PET (F-18 Florbetapir)",
            "detection_method_type": "imaging",
            "diagnostic_performance": "For best PET measures detecting beta-amyloid deposition reported in the literature: sensitivity 88-91%, specificity 80-84% (no confidence intervals provided in this paper).",
            "study_design": "Reported from literature summaries referenced in the paper (design details not specified in this article).",
            "sample_size": null,
            "population_characteristics": "Described generally as patients with suspected AD or MCI; exact cohorts for the quoted performance metrics are not specified in this paper.",
            "citation": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127",
            "uuid": "e7920.0",
            "source_info": {
                "paper_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease",
                "publication_date_yy_mm": "2025-04"
            }
        },
        {
            "name_short": "Tau propagation",
            "name_full": "Tau propagation / intracellular neurofibrillary tangles hypothesis",
            "brief_description": "Hypothesis that intracellular aggregation of hyperphosphorylated tau into neurofibrillary tangles impairs neuronal function and spreads in a stereotyped manner, driving disease progression and cognitive decline in AD.",
            "citation_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease",
            "mention_or_use": "mention",
            "hypothesis_name": "tau propagation",
            "hypothesis_description": "Intracellular accumulation of hyperphosphorylated tau forms tangles that disrupt neuronal cytoskeleton and synaptic function, contributing to neuronal death and correlating with clinical stage and progression of AD.",
            "supporting_evidence": "The paper reports direct visualization of tau pathology by tau PET (F-18 GTP1) in the presented case (temporoparietal tau accumulation), and notes that tau PET is critical for staging disease progression; the clinical trial enrollment of the patient into a tau-targeting monoclonal antibody (semorinemab) is cited as clinical translation of tau-targeted therapies.",
            "contradictory_evidence": "Paper does not present direct contradictory molecular evidence to tau hypothesis; it does note limitations in clinical-pathological concordance (amyloid/tau pathology present in ~85% of clinical AD), implying that tau pathology is not universally present in all clinically diagnosed cases.",
            "risk_factor": "Family history of early-onset Alzheimer's disease (patient's father)",
            "risk_factor_category": "genetic",
            "detection_method": "Tau PET (F-18 GTP1)",
            "detection_method_type": "imaging",
            "diagnostic_performance": "No numeric sensitivity/specificity provided for tau PET performance in this paper; its utility is described qualitatively (detects tau tangles, useful for staging).",
            "study_design": "Case report (this paper reports use of tau PET in a single patient) and literature discussion; broader performance metrics are not specified.",
            "sample_size": 1,
            "population_characteristics": "62-year-old right-handed female with progressive short-term memory loss, MMSE 26/30, family history of early-onset AD; enrolled in a tau-targeting clinical trial.",
            "citation": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127",
            "uuid": "e7920.1",
            "source_info": {
                "paper_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease",
                "publication_date_yy_mm": "2025-04"
            }
        },
        {
            "name_short": "Neurodegeneration (A/T/N 'N')",
            "name_full": "Neurodegeneration / neuronal injury biomarker (N in A/T/N)",
            "brief_description": "Neurodegeneration reflected by structural loss or hypometabolism (MRI atrophy, FDG-PET hypometabolism, CSF t-tau) used as a marker of neuronal injury and disease stage.",
            "citation_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease",
            "mention_or_use": "use",
            "hypothesis_name": "neurodegeneration (metabolic dysfunction / neuronal injury)",
            "hypothesis_description": "Neuronal injury and metabolic dysfunction (reflected as cortical atrophy on MRI and regional hypometabolism on FDG-PET) are downstream manifestations of AD pathology and correlate with cognitive impairment and disease stage.",
            "supporting_evidence": "In the case, MRI showed cortical atrophy (temporal/parietal) and F-18 FDG PET showed hypometabolism in bilateral temporal and parietal lobes—findings consistent with AD pattern; the paper references FDG-PET aiding differentiation of AD from other dementias and lists structural MRI and diffusion tensor imaging as methods to reveal atrophy and white matter changes.",
            "contradictory_evidence": "No direct contradictory evidence presented in this article; authors note that structural changes often appear later in disease progression, limiting early-detection utility.",
            "risk_factor": "Age (AD primarily affects individuals aged 65 and older as noted in the paper)",
            "risk_factor_category": "demographic/age",
            "detection_method": "FDG-PET (regional hypometabolism); MRI (cortical/hippocampal atrophy); diffusion tensor imaging (white matter microstructural changes)",
            "detection_method_type": "imaging",
            "diagnostic_performance": "Paper does not provide numeric diagnostic metrics for FDG-PET or MRI in this article beyond qualitative descriptions; FDG-PET pattern described qualitatively as 'suggestive of Alzheimer's disease pattern.'",
            "study_design": "Use in single-case clinical evaluation reported in this paper; referenced literature for general utility (designs not specified here).",
            "sample_size": 1,
            "population_characteristics": "Single 62-year-old female with MCI symptoms, MMSE 26/30; MRI and FDG-PET abnormalities consistent with AD pattern.",
            "citation": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127",
            "uuid": "e7920.2",
            "source_info": {
                "paper_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease",
                "publication_date_yy_mm": "2025-04"
            }
        },
        {
            "name_short": "CSF biomarker ratios",
            "name_full": "CSF Aβ42 / t-tau and Aβ42 / p-tau ratios",
            "brief_description": "Cerebrospinal fluid biomarker ratios combining Aβ42 with total tau or phosphorylated tau used to identify AD pathology and predict conversion in MCI patients.",
            "citation_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease",
            "mention_or_use": "mention",
            "hypothesis_name": "fluid-biomarker indication of Aβ/tau pathology",
            "hypothesis_description": "Altered CSF concentrations (reduced Aβ42 and increased t-tau/p-tau) and their ratios reflect underlying amyloid and tau pathologies and can identify patients with MCI likely due to AD.",
            "supporting_evidence": "The paper cites literature reporting high diagnostic performance for CSF Aβ42/t-tau and Aβ42/p-tau ratios in identifying MCI-AD: sensitivity 94-97% and specificity 83-85%; CSF biomarkers are described as well-validated for in vivo detection of AD pathology and used in research and clinical contexts.",
            "contradictory_evidence": "In the presented case, routine CSF analysis (cell count, glucose, protein) was unremarkable, illustrating that standard CSF testing (not specialized Aβ/tau assays) may be normal; the paper also references differences in timing between PET and CSF (amyloid PET may detect deposition earlier than CSF), indicating discordance in some situations.",
            "risk_factor": "Mild cognitive impairment (MCI) stage as the clinical context for CSF biomarker use",
            "risk_factor_category": "clinical stage",
            "detection_method": "CSF measurement of Aβ42, total tau (t-tau), and hyperphosphorylated tau (p-tau); use of Aβ42/t-tau and Aβ42/p-tau ratios",
            "detection_method_type": "fluid biomarker",
            "diagnostic_performance": "Reported in the paper from cited literature: sensitivity 94-97% and specificity 83-85% for identifying MCI patients with suspected AD (no further metrics or study-level detail provided here).",
            "study_design": "Reported from multi-cohort / literature studies cited in the article (exact designs not specified in this paper).",
            "sample_size": null,
            "population_characteristics": "Described for MCI patients suspected of AD (MCI-AD) in cited literature; this paper's case had routine CSF testing but not reported specialized Aβ/tau CSF results.",
            "citation": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127",
            "uuid": "e7920.3",
            "source_info": {
                "paper_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease",
                "publication_date_yy_mm": "2025-04"
            }
        },
        {
            "name_short": "Clinical cognitive assessment (MMSE)",
            "name_full": "Mini-Mental State Examination (MMSE)",
            "brief_description": "Brief clinician-administered cognitive screening tool used to quantify cognitive impairment; used here in initial neuropsychological assessment.",
            "citation_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease",
            "mention_or_use": "use",
            "hypothesis_name": "clinical cognitive dysfunction measurement",
            "hypothesis_description": "Cognitive screening tests detect clinical impairment that may prompt further biomarker-based evaluation; while useful, clinical tests alone often identify AD at later stages compared with biomarker approaches.",
            "supporting_evidence": "In the case, MMSE score was 26/30, demonstrating mild cognitive impairment; the paper emphasizes that traditional clinical/neuropsychological testing often identifies AD at a relatively late stage and supports the need for biomarker-based early detection.",
            "contradictory_evidence": "Authors state that clinical criteria have limited specificity for underlying AD neuropathology (only ~85% concordance), indicating MMSE and clinical assessment alone can be insufficient to reliably identify AD pathology.",
            "risk_factor": "Mild cognitive impairment (as indicated by lower MMSE scores)",
            "risk_factor_category": "clinical",
            "detection_method": "Mini-Mental State Examination (MMSE)",
            "detection_method_type": "cognitive test",
            "diagnostic_performance": "No numeric sensitivity/specificity provided in this paper for MMSE performance; MMSE score reported for single case (26/30).",
            "study_design": "Use in single-case clinical evaluation in this paper (case report).",
            "sample_size": 1,
            "population_characteristics": "Single 62-year-old female with progressive short-term memory loss and MMSE 26/30 (interpreted as mild cognitive impairment).",
            "citation": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease. Goel S A, Singh R, John R, Suthar P, Singh J S; 2025. DOI: 10.7759/cureus.83127",
            "uuid": "e7920.4",
            "source_info": {
                "paper_title": "Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease",
                "publication_date_yy_mm": "2025-04"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "NIA-AA Research Framework: toward a biological definition of Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "niaaa_research_framework_toward_a_biological_definition_of_alzheimers_disease"
        },
        {
            "paper_title": "Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions",
            "rating": 2,
            "sanitized_title": "imaging_tau_and_amyloidβ_proteinopathies_in_alzheimer_disease_and_other_conditions"
        },
        {
            "paper_title": "Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study",
            "rating": 2,
            "sanitized_title": "optimal_combinations_of_csf_biomarkers_for_predicting_cognitive_decline_and_clinical_conversion_in_cognitively_unimpaired_participants_and_mild_cognitive_impairment_patients_a_multicohort_study"
        },
        {
            "paper_title": "Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "considerations_in_the_clinical_use_of_amyloid_pet_and_csf_biomarkers_for_alzheimers_disease"
        },
        {
            "paper_title": "Lecanemab in early Alzheimer's disease",
            "rating": 1,
            "sanitized_title": "lecanemab_in_early_alzheimers_disease"
        }
    ],
    "cost": 0.011864,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease
04/28/2025</p>
<p>Shiv A Goel 
Department of Diagnostic Radiology and Nuclear Medicine
Rush University Medical Center
ChicagoUSA</p>
<p>DeepaRishab Singh 
Department of Diagnostic Radiology and Nuclear Medicine
Rush University Medical Center
ChicagoUSA</p>
<p>Regina John 
Department of Diagnostic Radiology and Nuclear Medicine
Rush University Medical Center
ChicagoUSA</p>
<p>Pokhraj Suthar 
Department of Diagnostic Radiology and Nuclear Medicine
Rush University Medical Center
ChicagoUSA</p>
<p>Jagadeesh S Singh jagadeesh_s_singh@rush.edu 
Department of Diagnostic Radiology and Nuclear Medicine
Rush University Medical Center
ChicagoUSA</p>
<p>East Suffolk and North Essex Trust NHS
Radiology, ColchesterGBR</p>
<p>Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease
04/28/20251AC67E86ACED084AB90BF04A282E625C10.7759/cureus.83127NeurologyRadiologyNuclear Medicine alzheimer's diseaseamyloid petearly detectionmild cognitive impairmentmolecular imagingtau pet
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by impairments in memory and cognitive abilities.The development of new immunotherapies targeting beta-amyloid (Aβ) and tau protein deposition in the brain is ushering in great advances in clinical management.Advances in molecular imaging techniques, particularly positron emission tomography (PET) with amyloid and tau tracers, have facilitated the early detection of Alzheimer's pathology.We report a case of a 67-year-old patient presenting with mild cognitive impairment (MCI) who was confirmed to have AD on newer PET imaging.This report highlights the important role of molecular imaging in the early diagnosis of AD before significant clinical and functional decline sets in, thereby emphasizing its role in clinical practice.</p>
<p>Introduction</p>
<p>With rising life expectancies, the prevalence of neurodegenerative diseases has surged globally.The World Health Organization predicts that dementia will affect 82 million individuals by 2030 [1].Each year, approximately 10 million new cases are reported, with Alzheimer's disease (AD) accounting for 60-70% of these cases [2][3].Beyond the societal and economic burdens, AD directly impacts individuals and their families profoundly.It is a progressive neurodegenerative disorder characterized by impairments in memory and cognitive abilities.Deposition of intracerebral beta-amyloid (Aβ) and intracellular accumulation of tau tangles leading to synaptic dysfunction and death of neuronal cells have been implicated as the pathogenesis in AD.The pathophysiological process of AD has been shown to occur many years before the diagnosis and clinical presentation of AD dementia.This long preclinical phase of AD could provide a critical opportunity for therapeutic intervention, given the development of novel immunotherapies that target and reduce the amount of Aβ and tau protein deposition in the brain, thereby slowing the disease process.</p>
<p>Early and accurate diagnosis of AD is crucial for patient management, therapeutic intervention, and the development of disease-modifying treatments.Traditional diagnostic approaches, which rely on clinical assessment including neuropsychological testing, often identify AD at a relatively late stage when significant neuronal damage has already occurred.A paradigm shift has emerged, from a clinical diagnosis based only on symptoms and cognitive testing to one that is increasingly supported by biomarkers, namely amyloid and Tau positron emission tomography (PET) scan or CSF analysis, enabling the identification of Aβ or tau protein present early in the disease.Newer PET imaging uses radiolabeled tracers that bind selectively to amyloid and tau proteins, allowing for direct visualization and quantification of these pathologic protein deposits.CSF biomarkers reflect biochemical changes associated with AD pathology, providing an indirect measure of the presence of Aβ plaques and tau tangles.With continued advances in the AD biomarker research, the role of amyloid and tau PET imaging is becoming increasingly important for the early detection and management of AD.</p>
<p>Case Presentation</p>
<p>A 62-year-old right-handed female presented with complaints of progressive short-term memory loss over the past year.She reported difficulty recalling recent events, finding words, and remembering the location of personal items.She also had a history of mood fluctuations, increasing anxiety, sleep disturbances, decreased concentration, and episodes of agitation.There was no history of suicidal ideations or hallucinations.She had no history of smoking or significant alcohol consumption.Regarding family history, her father had been diagnosed with early-onset AD in his late 50s and passed away at 63 years.</p>
<p>On initial clinical evaluation, the patient had no complaints of tremors, seizures, facial asymmetry, speech difficulties, weakness, or headaches.On neuropsychological examination, she appeared nervous and anxious but showed no signs of hallucinations or psychosis.As for mental status examination, she was awake, alert, and oriented to time, place, and person.Her speech was fluent with intact comprehension, repetition, and naming abilities.She exhibited impaired attention and delayed recall, as evidenced by her Mini-Mental State Examination (MMSE) score of 26/30.Laboratory investigations, such as routine blood counts, metabolic profile, thyroid function tests, and Vit B12 levels, were normal.Routine CSF analysis showed normal cell count, glucose, and protein levels.Based on clinical findings of mild to moderate memory and cognitive impairment and given the family history of early-onset Alzheimer's in her father, there was clinical suspicion of Alzheimer's dementia.To confirm clinical findings and exclude other less likely etiologies like intracranial lesion, epilepsy, or other types of dementia, the patient underwent neuroimaging.Initial MRI showed mild cortical atrophy without evidence of intracranial lesions (Figure 1).</p>
<p>FIGURE 1: T1-weighted MRI axial images (A,B) showing cortical atrophy in the temporal and parietal regions (arrows) MRI: magnetic resonance imaging</p>
<p>The patient subsequently underwent an F-18 FDG PET scan to confirm the type of dementia pattern.FDG PET showed hypometabolism in the bilateral temporal and parietal lobes, suggestive of Alzheimer's disease pattern (Figure 2).The patient was later referred to a University hospital where she was enrolled in research endeavors and underwent advanced PET imaging to detect the presence of beta-amyloid and tau protein.Amyloid PET (F-18 Florbetapir) demonstrated significant amyloid-beta deposition in the brain's grey matter (Figure 3).Tau PET (F-18 GTP1) confirmed tau protein accumulation in the temporoparietal regions (Figure 4).Based on these findings, a diagnosis of AD was confirmed.The patient was enrolled in a clinical trial involving semorinemab, a monoclonal antibody targeting tau pathology.She was also started on cognitive rehabilitation therapy and lifestyle modifications, physical activity, and cognitive exercises.</p>
<p>Surgical procedures none</p>
<p>Imaging Observations</p>
<p>MRI (brain)</p>
<p>Cortical atrophy without evidence of intracranial lesions (Figure 1)</p>
<p>F18-FDG PET scan Hypometabolism in the bilateral temporal and parietal lobes (Figure 2)</p>
<p>Amyloid PET (F-18 Florbetapir) Positive amyloid-beta deposition in the brain's grey matter (Figure 3)</p>
<p>Tau PET (F-18 GTP1) Positive tau protein accumulation in the temporoparietal regions (Figure 4)</p>
<p>Current referral</p>
<p>Clinical trials exploring semorinemab, a monoclonal antibody targeting tau pathology</p>
<p>Discussion</p>
<p>AD primarily affects individuals aged 65 and older, with early-onset cases occurring in less than 10% of patients.Symptoms, including memory impairment and cognitive decline, often begin more than a decade before clinical diagnosis.Early-onset AD has been linked to genetic mutations, such as those involving the APOE gene.The pathophysiology involves extracellular amyloid-beta plaques and intracellular tau tangles, leading to synaptic dysfunction and neuronal death [4,5,6].Early and accurate diagnosis of AD is crucial for patient management and therapeutic intervention.Traditional diagnostic approaches, relying on clinical assessment including neuropsychological testing, often identify AD at a relatively late stage when significant neuronal damage has already occurred.Moreover, neuropathological studies show that amyloid plaques and neurofibrillary tangles are found in only about 85% of cases with a clinical diagnosis of AD dementia, highlighting the limited specificity of clinical criteria in detecting AD neuropathology [7].Hence, there is an increasing emphasis on the clinical use of biomarkers to facilitate early and specific diagnosis of AD.</p>
<p>Two biomarker modalities are now well-validated and approved components in the diagnostic workup of AD patients in clinical settings.Advanced amyloid and tau PET imaging and CSF biomarkers enable in vivo detection of cerebral amyloid and tau pathology and provide critical insights into the underlying disease mechanisms, aiding in the identification of AD pathological changes even at the preclinical or mild cognitive impairment (MCI) stages of AD [8].Amyloid and Tau PET imaging uses novel radiolabeled tracers that bind selectively to amyloid and tau proteins, allowing for direct visualization and quantification of these pathologic protein deposits, previously only possible through histopathological examination.When combined with advanced MRI techniques and CSF biomarkers, these modalities enhance diagnostic accuracy and enable tailored interventions in the prodromal stage of the disease [9,10].MRI with diffusion tensor imaging can reveal structural changes, such as hippocampal and cortical atrophy, although these changes appear later in disease progression.Diffusion tensor imaging can identify white matter microstructural changes.FDG-PET detects hypometabolism in specific brain regions, aiding in differentiating AD from other dementias.Amyloid PET provides in vivo visualization of amyloid plaque deposition, a hallmark of AD.Tau PET detects tau tangles, critical for staging disease progression.</p>
<p>The integration of amyloid and tau imaging into clinical practice is facilitated by the "A/T/N" biomarker classification system [11][12].In the proposed A/T/N classification system, the AD biomarkers are divided into three binary classes: "A" refers to the value of an Aβ biomarker (amyloid PET or CSF Aβ42); "T," the value of a tau pathology biomarker (CSF p-tau or tau PET); and "N," a quantitative or topographic biomarker of neurodegeneration or neuronal injury (CSF t-tau, FDG-PET, or structural MRI).Advanced PET imaging and CSF biomarkers are now established tools in the diagnostic workup of AD patients, and their use is anticipated to increase with the introduction of new disease-modifying therapies.</p>
<p>Although these biomarkers are comparable alternatives in research settings to determine amyloid status, biomarker testing in clinical practice requires careful consideration of the strengths and limitations of each modality, as well as the specific clinical context, to identify which test is best suited for each patient.Current literature suggests that both advanced PET imaging and CSF biomarkers will continue to play an increasingly important role in the diagnostic workup of patients with AD.The best PET measures performed for the presence of beta-amyloid deposition in the brain showed a sensitivity of 88-91% and specificity of 80-84%.The best CSF measures for identifying patients with MCI and suspected AD (MCI-AD) were CSF measurement of Aβ42/total tau (t-tau) and Aβ42/hyperphosphorylated tau (p-tau) ratios, with a sensitivity of 94-97% and a specificity of 83-85% [13][14][15].</p>
<p>These two biomarkers have also played a pivotal role in the design and implementation of clinical trials for AD.These biomarkers have been successfully used to select participants for clinical trials using diseasemodifying drugs, including the approved drugs aducanumab and lecanemab, allowing for the exclusion of those patients with clinical AD but who do not have biomarker evidence for Aβ pathology, and thus would not benefit from treatment [16].However, in clinical settings, amyloid PET quantification has been well validated and helps in assessing amyloid deposition clearance and in supporting treatment discontinuation decisions.In summary, advanced amyloid and tau PET imaging, along with CSF biomarkers, allow clinicians to identify AD in its preclinical stage, enabling earlier interventions with immunotherapies and more precise management strategies [17][18][19].</p>
<p>Conclusions</p>
<p>AD is a progressive neurodegenerative disease associated with substantial personal and societal challenges.</p>
<p>Early detection of AD through advanced molecular imaging, such as amyloid and tau PET along with CSF biomarkers, represents a paradigm shift in its diagnosis and treatment.With continued advances in the AD biomarker research and increasing availability of disease-modifying immunotherapies, these molecular imaging modalities will play an essential role in early diagnosis, patient selection, and timely therapeutic intervention.</p>
<p>FIGURE 2 :
2
FIGURE 2: FDG-PET images (A: axial, B: coronal, C: sagittal) displaying hypometabolism in bilateral temporo-parietal lobes (red arrows) FDG-PET: fluorodeoxyglucose positron emission tomography</p>
<p>FIGURE 3 :
3
FIGURE 3: 18F-Florbetapir axial PET images (A: grey scale, B: fused axial image) showing extensive beta-amyloid deposition in the cortical regions (grey matter) of the brain (red arrows) PET: positron emission tomography</p>
<p>FIGURE 4 :
4
FIGURE 4: 18F-GTP1 tau PET images (A: axial, B: sagittal fused images) illustrating tau protein accumulation in temporo-parietal regions (red arrows) PET: positron emission tomography</p>
<p>Table 1
1
provides a summary of the patient's clinical findings and imaging results.</p>
<p>2025 Goel et al.Cureus 17(4): e83127.DOI 10.7759/cureus.831273 of 6 Clinical</p>
<p>findings and imaging results Clinical finding Result/observation
Patient age, years62DiagnosisAlzheimer's diseasePresenting symptomsProgressive short-term memory loss, difficulty in recalling recent events, finding words, and remembering the location of personal itemsFamily historyEarly-onset Alzheimer's disease in the fatherLab findingsCBC, TSH, vitamin B12, and CSF analysis were unremarkable</p>
<p>TABLE 1 : Summary of clinical findings and imaging results
1
CBC: complete blood count; CSF: cerebrospinal fluid; FDG-PET: fluorodeoxyglucose positron emission tomography; MRI: magnetic resonance imaging; TSH: thyroid-stimulating hormone</p>
<p>Goel et al. Cureus 17(4): e83127. DOI 10.7759/cureus.83127
AcknowledgementsShiv Goel and Rishab Singh contributed equally to the work and should be considered co-first authors 2025 Goel et al.Cureus 17(4): e83127.DOI 10.7759/cureus.83127Additional Information Author ContributionsAll authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.Concept and design: Jagadeesh S. Singh, Pokhraj Suthar, Deepa Regina John Acquisition, analysis, or interpretation of data: Jagadeesh S. Singh, Pokhraj Suthar, Shiv A. Goel, Deepa Regina John, Rishab Singh Drafting of the manuscript: Jagadeesh S. Singh, Pokhraj Suthar, Shiv A. Goel, Deepa Regina John, Rishab Singh Critical review of the manuscript for important intellectual content: Jagadeesh S. Singh, Pokhraj Suthar, Deepa Regina John Supervision: Jagadeesh S. Singh, Pokhraj SutharDisclosuresHuman subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study.Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
World Health Organization. Dementia: fey facts. 2023. August 9. 2024</p>
<p>Alzheimer's disease: what is Alzheimer's disease?. 2024. August 9, 2024Centers for Disease Control and Prevention</p>
<p>Alzheimer's disease: facts and figures. 2024. August 9. 2024Alzheimer's Association</p>
<p>What is Alzheimer's disease?. 2024. August 9. 2024National Institute on Aging</p>
<p>. A Kumar, J Sidhu, F Lui, J W Tsao, 2024Alzheimer Disease. StatPearls PublishingTreasure Island, FL</p>
<p>NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Jack CrJr, D A Bennett, K Blennow, 10.1016/j.jalz.2018.02.018Alzheimers Dement. 142018</p>
<p>Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. T G Beach, S E Monsell, L E Phillips, W Kukull, 10.1097/NEN.0b013e31824b211bJ Neuropathol Exp Neurol. 712012</p>
<p>Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study. G Salvadó, V Larsson, K A Cody, 10.1002/alz.12907Alzheimers Dement. 192023</p>
<p>Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. V L Villemagne, V Doré, S C Burnham, C L Masters, C C Rowe, 10.1038/nrneurol.2018.9Nat Rev Neurol. 142018</p>
<p>Brain imaging in Alzheimer disease . Cold Spring Harb Perspect Med. K A Johnson, N C Fox, R A Sperling, W E Klunk, 10.1101/cshperspect.a00621320122</p>
<p>Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. B Dubois, H H Feldman, C Jacova, 10.1016/S1474-4422(14)70090-0Lancet Neurol. 132014</p>
<p>Alzheimer disease": multiple meanings separated by a common name. D S Knopman, R C Petersen, C R JackJr, 10.1212/WNL.0000000000007583A brief history of. 201992</p>
<p>Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study. N Guillen, J Contador, M Buongiorno, 10.1007/s00406-023-01701Eur Arch Psychiatry Clin Neurosci. 2752025</p>
<p>Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers. V J Lowe, C T Mester, E S Lundt, 10.1002/alz.14317Alzheimers Dement. 202024</p>
<p>Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease. A Leuzy, A Bollack, D Pellegrino, 10.1002/alz.14528Alzheimers Dement. 212025</p>
<p>Lecanemab in early Alzheimer's disease. C H Van Dyck, C J Swanson, P Aisen, 10.1056/NEJMoa2212948N Engl J Med. 3882023</p>
<p>Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD. M F Mendez, 10.1016/j.arcmed.2012.11.009Arch Med Res. 432012</p>
<p>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. R A Sperling, P S Aisen, L A Beckett, 10.1016/j.jalz.2011.03.003Alzheimers Dement. 72011</p>
<p>Tau biomarkers in Alzheimer's disease: toward implementation in clinical practice and trials. R Ossenkoppele, R Smith, N Mattsson, 10.1016/S1474-4422(22)00148-1Lancet Neurol. 212022</p>
<p>. Goel, 10.7759/cureus.831276of6Cureus. 174e831272025</p>            </div>
        </div>

    </div>
</body>
</html>